Last reviewed · How we verify
Aspirin First
Aspirin inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins and thromboxane, thereby decreasing inflammation and preventing platelet aggregation.
Aspirin inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins and thromboxane, thereby decreasing inflammation and preventing platelet aggregation. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Pain and fever relief, Rheumatoid arthritis and other inflammatory conditions.
At a glance
| Generic name | Aspirin First |
|---|---|
| Sponsor | University of Pennsylvania |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Inflammation |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly acetylates COX-1 and COX-2 enzymes, blocking the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet clumping). This dual action makes aspirin effective both as an anti-inflammatory analgesic and as an antiplatelet agent for cardiovascular protection. At low doses, the antiplatelet effect predominates; at higher doses, anti-inflammatory effects are more pronounced.
Approved indications
- Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)
- Pain and fever relief
- Rheumatoid arthritis and other inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Increased bleeding risk
- Allergic reactions (in aspirin-sensitive individuals)
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE) (NA)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The Combined First Trimester Screening
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- SIMPLAAFY Clinical Trial (NA)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin First CI brief — competitive landscape report
- Aspirin First updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI